التفاصيل البيبلوغرافية
| العنوان: |
Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure. |
| المؤلفون: |
Harada, Guilherme1 guiarada@hotmail.com, Costa Santini, Fernando1, Nogueira Amorim Canedo, Felipe Sales1, de Carvalho Oliveira, Leandro Jonata1, Bortot Zuppani, Henrique2, De Castro Jr., Gilberto1 |
| المصدر: |
Ecancermedicalscience. 2019, Vol. 13 Issue 962-995, p1-5. 5p. |
| مصطلحات موضوعية: |
*PNEUMONIA, *NON-small-cell lung carcinoma, *CENTRAL nervous system, *PROTEIN-tyrosine kinases, *BRAIN metastasis |
| مستخلص: |
Osimertinib is a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR mutations. Pneumonitis is a severe adverse event (AE) related to osimertinib treatment which appears to be more frequent when associated with concurrent or previous anti-PD(L)1 exposure. Data regarding the efficacy and safety of osimertinib rechallenge, especially in the setting of central nervous system (CNS) metastases, are scarce. We herein describe a case of a 53-year-old patient with metastatic EGFR-mutated NSCLC, who developed pneumonitis after osimertinib treatment and was successfully rechallenged with 40 mg daily osimertinib, with CNS response. This dose reduction strategy may be an option for selected patients with brain metastases after tyrosine kinase inhibitors-induced AEs. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder